- Home
- LYEL vs PBYI Comparison
LYEL vs PBYI Comparison
Compare LYEL & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- PBYI
- Stock Information
- Founded
- LYEL 2018
- PBYI 2010
- Country
- LYEL United States
- PBYI United States
- Employees
- LYEL N/A
- PBYI N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- PBYI Health Care
- Exchange
- LYEL Nasdaq
- PBYI Nasdaq
- Market Cap
- LYEL 207.7M
- PBYI 171.7M
- IPO Year
- LYEL 2021
- PBYI N/A
- Fundamental
- Price
- LYEL $10.76
- PBYI $5.25
- Analyst Decision
- LYEL Sell
- PBYI Strong Buy
- Analyst Count
- LYEL 2
- PBYI 1
- Target Price
- LYEL $15.00
- PBYI $7.00
- AVG Volume (30 Days)
- LYEL 47.2K
- PBYI 910.5K
- Earning Date
- LYEL 08-12-2025
- PBYI 08-07-2025
- Dividend Yield
- LYEL N/A
- PBYI N/A
- EPS Growth
- LYEL N/A
- PBYI 434.29
- EPS
- LYEL N/A
- PBYI 0.97
- Revenue
- LYEL $60,000.00
- PBYI $238,062,000.00
- Revenue This Year
- LYEL N/A
- PBYI N/A
- Revenue Next Year
- LYEL N/A
- PBYI N/A
- P/E Ratio
- LYEL N/A
- PBYI $5.39
- Revenue Growth
- LYEL 11.11
- PBYI 8.63
- 52 Week Low
- LYEL $7.65
- PBYI $2.23
- 52 Week High
- LYEL $32.40
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- LYEL 49.97
- PBYI 70.56
- Support Level
- LYEL $10.49
- PBYI $4.81
- Resistance Level
- LYEL $11.00
- PBYI $5.40
- Average True Range (ATR)
- LYEL 0.72
- PBYI 0.49
- MACD
- LYEL -0.11
- PBYI 0.10
- Stochastic Oscillator
- LYEL 52.86
- PBYI 72.85
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.